RFK Jr. is personally endorsing peptides

Signals Inbox·July 26, 2026·Consumer Health

RFK Jr. says he is a big fan of peptides and has personally used them to treat injuries. That would normally be another celebrity wellness endorsement. The tension is that Kennedy now runs America’s health department while his FDA considers making several experimental peptides easier for compounding pharmacies to sell.

Q1What is the official source?

The FDA meeting page confirms that its Pharmacy Compounding Advisory Committee reviewed seven peptides on July 23 and 24, including BPC-157, TB-500, MOTS-C, epitalon, Semax, KPV, and emideltide. Kennedy separately told STAT that he is a big fan of peptides and has used them himself with good results on injuries.

Q2Why does his personal use matter?

Because Kennedy is not just another wellness influencer. He is the U.S. health secretary and oversees the department containing the FDA. His personal support gives the peptide movement political power at the exact moment regulators are deciding whether compounding pharmacies should get wider access to these substances.

Q3What peptides are we talking about?

The debate mainly covers experimental compounds sold for recovery, wound healing, inflammation, weight loss, sleep, longevity, and mental performance. BPC-157 and TB-500 are two of the best-known examples. They are popular in gyms, longevity clinics, podcasts, and online biohacking groups, but neither has normal FDA approval for those uses.

Q4What did the FDA panel decide?

The panel narrowly supported allowing several peptides to be used by compounding pharmacies. One important vote was 8 to 6, with one abstention. That is not full FDA approval, and the agency does not have to follow the panel. But it creates a real path for compounds now bought through a messy gray market to enter regulated clinics and pharmacies.

Q5How strong is the evidence?

For several compounds, it is weak. FDA scientists said BPC-157 studies were small, short, and often exploratory. For TB-500, they said they could not find human studies using the compound. The problem is not that every peptide is fake. Insulin and GLP-1 medicines are peptides too. The problem is that popularity is moving much faster than reliable human data.

Q6What is the real point of tension?

The person overseeing U.S. health policy personally believes in compounds his own scientists say lack enough evidence. Kennedy argues that supervised pharmacy access is safer than making people buy mystery products online. Critics see the opposite risk: government legitimacy arriving before proper trials, safety data, and manufacturing standards.

Q7So what changes next?

If the FDA follows the panel, peptides could move from overseas sellers and research-only websites into American prescriptions, telehealth platforms, clinics, and licensed compounding pharmacies. That would not make them proven medicines, but it could turn a fringe biohacking market into a mainstream consumer-health category almost overnight.